The National Hemophilia Foundation has been notified of an alert issued by Novo Nordisk regarding a shipment of NovoSeven Coagulation Factor VIIa (Recombinant) that is missing from a storage facility. The specific product and lot number are included in this release from Novo Nordisk along with contact information in the event that you do encounter the lot number specified. At this time, there is no indication that this material entered any distribution channel. As advised by the company, this lot of product should NOT be used under any circumstances.
PHYSICIANS: Please distribute this information to all providers in your area who treat patients with hemophilia.
CHAPTERS: Please distribute this information to your membership.
Please sign up for the Patient Notification System (PNS) to be notified directly about the latest recall or withdrawal of recombinant and plasma products. The System is confidential and time sensitive. It is administered by an independent third-party organization and is free of charge.
To enroll in the PNS, please go online at http://www.patientnotificationsystem.org/
This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends treatment for specific individuals and in all cases recommend that you consult your physician or local hemophilia treatment center before pursuing any course of treatment.